Pharmacodynamics of voriconazole in a dynamic in vitro model of invasive pulmonary aspergillosis: implications for in vitro susceptibility breakpoints.
about
Combination of voriconazole and anidulafungin for treatment of triazole-resistant aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosisPharmacodynamics of Isavuconazole for Invasive Mold Disease: Role of Galactomannan for Real-Time Monitoring of Therapeutic Response.Antifungal pharmacokinetics and pharmacodynamicsPharmacodynamics of Isavuconazole in a Dynamic In Vitro Model of Invasive Pulmonary AspergillosisSoftware for dosage individualization of voriconazole for immunocompromised patientsInteraction of the pathogenic mold Aspergillus fumigatus with lung epithelial cells.Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.Pharmacodynamics for antifungal drug development: an approach for acceleration, risk minimization and demonstration of causality.Prognostic value of galactomannan: current evidence for monitoring response to antifungal therapy in patients with invasive aspergillosis.Voriconazole pharmacokinetics following HSCT: results from the BMT CTN 0101 trial.Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model.Pharmacodynamics of the Novel Antifungal Agent F901318 for Acute Sinopulmonary Aspergillosis Caused by Aspergillus flavus.Pharmacokinetic Modeling of Voriconazole To Develop an Alternative Dosing Regimen in Children.Pharmacodynamics of Voriconazole for Invasive Pulmonary Scedosporiosis.A strategy for designing voriconazole dosage regimens to prevent invasive pulmonary aspergillosis based on a cellular pharmacokinetics/pharmacodynamics model.
P2860
Q28727508-929D63E5-F35C-4500-8916-BD900B120F04Q33696043-9728A597-D4AB-4B2B-B590-CA4A2BCA9823Q35663841-1000D05F-34F8-4EF5-B020-25D5F384FB25Q36439102-780CE37E-505A-493D-B2D5-C3B3699B02A0Q36757595-0D10E58E-C5FF-4BE1-B962-4739CEBD4805Q38051328-A7916DD3-56B6-4977-8152-A32C2C356847Q38681635-C2D370EB-5434-490D-99FA-B2EFCC7966CAQ38919690-8EE0FFC2-C368-4BFC-B654-41D97AAA58F3Q39127825-045F814B-475E-4B2F-8E0C-C0201C6222EEQ39816665-38357328-5E9D-49A9-B02A-80DEDDDC55ADQ42227869-4AF6D91F-84E4-4553-AB29-C2FEC269F2E2Q46583730-050954A3-096C-40E5-9F2A-F94B47C8F439Q47781187-85B0A119-105D-4D86-BA32-2910FBE6669DQ50028191-3B547D94-9A95-4AA0-A6DF-AD821758B948Q55479804-81630F14-ECB7-4097-BA36-6A912736C0E4
P2860
Pharmacodynamics of voriconazole in a dynamic in vitro model of invasive pulmonary aspergillosis: implications for in vitro susceptibility breakpoints.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Pharmacodynamics of voriconazo ...... ro susceptibility breakpoints.
@en
Pharmacodynamics of voriconazo ...... ro susceptibility breakpoints.
@nl
type
label
Pharmacodynamics of voriconazo ...... ro susceptibility breakpoints.
@en
Pharmacodynamics of voriconazo ...... ro susceptibility breakpoints.
@nl
prefLabel
Pharmacodynamics of voriconazo ...... ro susceptibility breakpoints.
@en
Pharmacodynamics of voriconazo ...... ro susceptibility breakpoints.
@nl
P2093
P2860
P50
P356
P1476
Pharmacodynamics of voriconazo ...... tro susceptibility breakpoints
@en
P2093
Adam R Jeans
Jayesh B Majithiya
Joanne Goodwin
Lea Gregson
Manuel Cuenca-Estrella
Peter A Warn
Zaid Al-Nakeeb
P2860
P304
P356
10.1093/INFDIS/JIS372
P407
P577
2012-05-25T00:00:00Z